The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“Am J Alzheimers Dis Other Demen 2011; 26(5):”
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Fitness Effects on the Cognitive Function of Older Adults: A Meta-Analytic Study
Colcombe, S., & Kramer, A. F. (2003) · Psychological Science · doi:10.1111/1467-9280.t01-1-01430 · Cited by 3,782
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Fixed-and random-effects models in meta-analysis.
Hedges, L. V., & Vevea, J. L. (1998) · Psychological Methods · doi:10.1037/1082-989x.3.4.486 · Cited by 2,977
Estimating effect sizes from pretest-posttest-control group designs
Morris, S. B. (2008) · Organizational Research Methods · doi:10.1177/1094428106291059 · Cited by 2,133
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Larson, E. B., Wang, L., Bowen, J. D., McCormick, W. C., Teri, L., Crane, P., & Kukull, W. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00004 · Cited by 1,463
Petersen, R. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp0910237 · Cited by 1,289
Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial
Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., Plymate, S. R., Fishel, M. A., Watson, G. S., Cholerton, B. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.307 · Cited by 1,171 · cited 2×
“…p<.01 Test for Overall Effect: Z=4.69, p<.01 −0.50 0.50 1.50 Favours Control − Favours Exercise Scherder et al. 2005 v.Uffelen et al. 2008 (walking) Lautenschlager et al. 2008 Baker et al. 2010 Varela et al. 2011 (60% HRR) Suzuki et al. 2013 15 77 48 19 16 47 15 75 52 10 15 45 2.88% 0.05 [ −0.43…”
InfluentialPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“AD Donezepil 18 (0-35) 19 (6-33) 12-54 weeks AD Galantamine 25 (8-49) 16 (9-26) 12-28 weeks AD Ginkgo 9 (2-28) 8 (3-23) 12-26 weeks AD Memantine 17 (3-34) 17 (2-33) 24 weeks-22 months AD Rivastigmine 24 (13-33) 13 (6-16) 12-24 weeks MCI drug 40 (32-43) 27 (17-31) 24 weeks -48 months AD exercise 5 (0-20) 17 (2-25) 6-24…”
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892 · cited 1×
“…Studies −0.50 −0.12 0.25 0.62 1.00 Favours Placebo Favours Drug Homma et al. 2008 (5mg) Homma et al. 2008 (10mg) Black et al. 2007 Winblad et al. 2006 Courtney et al. 2004 Seltzer et al. 2004 Tune et al. 2003 Feldman et al. 2001 Mohs et al. 2001 Tariot et al. 2001 Winblad et al. 2001 Homma et al.…”
InfluentialSynthesizing standardized mean‐change measures
Becker, B. J. (1988) · British Journal of Mathematical and Statistical Psychology · doi:10.1111/j.2044-8317.1988.tb00901.x · Cited by 889
Podewils, L. J. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi092 · Cited by 675
Naci, H., & Ioannidis, J. P. A. (2013) · BMJ · doi:10.1136/bmj.f5577 · Cited by 630
Gates, N., Fiatarone Singh, M. A., Sachdev, P. S., & Valenzuela, M. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.02.018 · Cited by 355
Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): A Randomized Controlled Trial
Pitkälä, K. H., Pöysti, M. M., Laakkonen, M.-L., Tilvis, R. S., Savikko, N., Kautiainen, H., & Strandberg, T. E. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.359 · Cited by 304 · cited 1×
“AD Donezepil 18 (0-35) 19 (6-33) 12-54 weeks AD Galantamine 25 (8-49) 16 (9-26) 12-28 weeks AD Ginkgo 9 (2-28) 8 (3-23) 12-26 weeks AD Memantine 17 (3-34) 17 (2-33) 24 weeks-22 months AD Rivastigmine 24 (13-33) 13 (6-16) 12-24 weeks MCI drug 40 (32-43) 27 (17-31) 24 weeks -48 months AD exercise 5 (0-20) 17 (2-25) 6-24…”
Kemoun, G., Thibaud, M., Roumagne, N., Carette, P., Albinet, C., Toussaint, L., Paccalin, M., & Dugué, B. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000272435 · Cited by 273 · cited 2×
“…All Studies Test for Heterogeneity: Q(df=3)=7.82, p=.05 Test for Overall Effect: Z=6.88, p<.01 −0.50 0.75 1.38 2.01 Favours Control − Favours Exercise Steinberg et al. 2009 Kemoun et al. 2010 Vreugdenhil et al. 2011 Venturelli et al. 2011 14 16 20 11 13 15 20 10 3.71% 0.48 [ −0.75 , 1.70 ] 25.32%…”
InfluentialFox, C., Crugel, M., Maidment, I., Auestad, B. H., Coulton, S., Treloar, A., Ballard, C., Boustani, M., Katona, C., & Livingston, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035185 · Cited by 173
Ito, K., Corrigan, B., Romero, K., Anziano, R., Neville, J., Stephenson, D., & Lalonde, R. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130575 · Cited by 62 · cited 1×
“AD Donezepil 18 (0-35) 19 (6-33) 12-54 weeks AD Galantamine 25 (8-49) 16 (9-26) 12-28 weeks AD Ginkgo 9 (2-28) 8 (3-23) 12-26 weeks AD Memantine 17 (3-34) 17 (2-33) 24 weeks-22 months AD Rivastigmine 24 (13-33) 13 (6-16) 12-24 weeks MCI drug 40 (32-43) 27 (17-31) 24 weeks -48 months AD exercise 5 (0-20) 17 (2-25) 6-24…”
Cited by
Frailty in Older Adults Undergoing Aortic Valve Replacement
Afilalo, J., Lauck, S., Kim, D. H., Lefèvre, T., Piazza, N., Lachapelle, K., Martucci, G., Lamy, A., Labinaz, M., Peterson, M. D., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.024 · Cited by 818
State of the science on mild cognitive impairment (MCI)
Anderson, N. D. (2019) · CNS Spectrums · doi:10.1017/s1092852918001347 · Cited by 541
Perez Ortiz, J. M., & Swerdlow, R. H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14585 · Cited by 426
Dauwan, M., Begemann, M. J. H., Slot, M. I. E., Lee, E. H. M., Scheltens, P., & Sommer, I. E. C. (2021) · Journal of Neurology · doi:10.1007/s00415-019-09493-9 · Cited by 239
Biazus-Sehn, L. F., Schuch, F. B., Firth, J., & Stigger, F. D. S. (2020) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2020.104048 · Cited by 194
Metadata
- Authors
- Ströhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., Hellweg, R., Priller, J., Rapp, M. A., & Rieckmann, N.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 23
- Issue
- 12
- Pages
- 1234-1249
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W1000383428
- Cited by
- 212
- References
- 24
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.